Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What Does 2018 Hold For Biopharma?

Dec 29 2017

• By Eleanor Malone

Scrip Perspectives, 2017-2018

Related Content

Roche's Neuroscience Franchise Gets Lift From Huntington's Breakthrough

Dec 12 2017

Spark's Luxturna Approval Ushers In A New Gene Therapy Era

Dec 19 2017

Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

Dec 06 2017

Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah

Oct 19 2017

Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy

Aug 29 2017

Related Companies

Boehringer Ingelheim GmbH

AstraZeneca PLC

Bristol Myers Squibb Company

Merck & Co., Inc.

AbbVie Inc.

Roche Holding AG

Spark Therapeutics, Inc.

Gilead Sciences, Inc.

Kite Pharma, Inc.

Genetix Biotherapeutics

Eli Lilly and Company

Novartis AG

Teva Pharmaceutical Industries Ltd.

Sanofi

ViiV Healthcare

Medidata Solutions Inc.

Pfizer Inc.

Additional Topics

Commercial Strategy Innovation ImmunoOncology Pricing Strategies Reimbursement Clinical Trials Brexit Personalized Medicine Approvals BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window